HealthNews

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors – PR Newswire

August 1, 2025
Less than a minute

  1. FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors  PR Newswire
  2. European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors  Yahoo Finance
  3. FDA approves concizumab-mtci for hemophilia A/B without inhibitors in patients 12 years and older  Contemporary Pediatrics
  4. Novo Nordisk’s Alhemo Recommended for Expanded Use in Europe for Haemophilia A and B  Insider Monkey
  5. European Medicines Agency Issues Positive Opinion for Concizumab Label Update in Hemophilia  Docwire News

Source link

Related posts:

  1. New leukemia drug offers hope for children and adults
  2. Cabinet approves call for local bids to supply medicines in 2026
  3. FDA to consider warning against antidepressants | National
  4. FDA considers removing warning labels on hormone replacement therapies : Shots
See also  Netflix just added this epic gladiator series — you can binge-watch all 39 episodes now
Tags
August 1, 2025
Less than a minute
Photo of Digit

Digit

Digit is a versatile content creator with expertise in Health, Technology, Movies, and News. With over 7 years of experience, he delivers well-researched, engaging, and insightful articles that inform and entertain readers. Passionate about keeping his audience updated with accurate and relevant information, Digit combines factual reporting with actionable insights. Follow his latest updates and analyses on DigitPatrox.
Back to top button
close